Last reviewed · How we verify
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
The Primary purpose of this study is to identify the recommended Phase 2 dose \[RP2D(s)\] for JNJ-63723283 in Part 1, to assess the anti-tumor activity of JNJ-63723283 at the RP2D(s) in participants with selected advanced cancers including non-small-cell lung cancer (NSCLC), melanoma, renal, bladder, small-cell lung cancer (SCLC), gastric/esophageal cancer, and high-level microsatellite instability (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer (CRC) in Part 2, to determine one or more additional RP2Ds in Parts 3 and 4.
Details
| Lead sponsor | Janssen Research & Development, LLC |
|---|---|
| Phase | PHASE1, PHASE2 |
| Status | ACTIVE_NOT_RECRUITING |
| Enrolment | 413 |
| Start date | Mon Nov 21 2016 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Dec 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Neoplasms
Interventions
- JNJ-63723283
Countries
Russia, Sweden, United Kingdom, Poland, Moldova, United States, Spain